



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



**Lactate dehydrogenase level as a COVID-19 severity marker**




We read with great interest the article by Henry et al. [1] showed that elevated lactate dehydrogenase (LDH) values were associated with 6-fold increased odds of severe COVID-19 disease. Lactate dehydrogenase increases in the early stage of myocardial infarction as well as in states of hemolysis. It is most active in the liver, striated muscles, heart, kidneys, lungs, brain, and red blood cells (erythrocytes). In the case of cell damage, lactate dehydrogenase is released from inside them, its concentration and activity in the blood increase. High serum LDH activity is a negative prognostic factor in such patients. LDH is a marker of various inflammatory states, e.g., infections, malignancies, MI, sepsis, or cardio-pulmonary compromise. Denese et al. showed that lactate dehydrogenase is a potential marker of vascular permeability in immune-mediated lung injury [2]. Early data Henry et al. reported in COVID-19 patients have suggested significant

differences in LDH levels between patients and without the severe disease [3].

A systematic review and meta-analysis were performed to verify the usefulness of using lactate dehydrogenase as a predictor of a patient's severity with COVID-19.

Two authors (M.P. and L.S.) searched electronic resources (Medline, EMBASE, and the Cochrane Central register from databases inception to 9 November 2020). A review of the bibliographies of the relevant articles was also performed. The retrieved articles were screened for relevance on title and abstract, followed by two independent investigators (L.S. and J.S.). The key search words were: „lactate dehydrogenase” OR „LDH” AND „COVID-19” OR „SARS-CoV-2”.

All statistical analyses were performed with Review Manager Software 5.4 (The Cochrane Collaboration, Oxford, Copenhagen, Denmark). All results are presented with their 95% confidence interval (CI). When the continuous outcome was reported in a study as median, range, and interquartile range, we estimated means and standard deviations using the formula described by Hozo et al. [4]. The random-effects model was used for  $I^2 > 50\%$ .  $P < 0.05$  was taken to show statistical significance. Statistical testing was two-tailed.



**Fig. 1.** Forest plot of lactate dehydrogenase level in sever vs. non-sever group. The center of each square represents the weighted mean difference for individual trials, and the corresponding horizontal line stands for a 95% confidence interval. The diamonds represent pooled results.

Twenty-eight studies reported LDH levels in severe vs. non-severe groups. The level of LDH in the individual groups varied (MD = 154.49; 95% CI: 121.24, 191.73;  $P < 0.001$ ,  $I^2 = 99\%$ ; Fig. 1). A statistically significant higher level of LDH was also observed in terms of ICU vs. Non-ICU (MD = 272.98; 95% CI: 195.46, 350.51;  $p < 0.001$ ;  $I^2 = 99\%$ ), patients and in nonsurvival patients vs. survival patients (MD = 259.21; 95% CI: 166.91, 351.51;  $p < 0.001$ ,  $I^2 = 100\%$ ). Supplementary Digital Content, SDC). The full list of publications included in this meta-analysis is presented in SDC.

In conclusion, the current meta-analysis confirmed that lactate dehydrogenase level can be used as a COVID-19 severity marker and is a predictor of survival.

### Declaration of Competing Interest

Authors don't declare any conflict of interest.

### Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ajem.2020.11.025>.

### References

- [1] Henry BM, Aggarwal G, Wong J, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. *Am J Emerg Med.* 2020 Sep;38(9):1722–6. <https://doi.org/10.1016/j.ajem.2020.05.073>.
- [2] Danese E, Montagnana M. An historical approach to the diagnostic biomarkers of acute coronary syndrome. *Annals of translational medicine.* 2016;4(10):194–6.
- [3] Henry B, De Olivera MHS, S. B, M. P, G. L Hematologic, biochemical and immune marker abnormalities associated with severe illness and mortality in corona virus disease 2019 (COVID 19): a meta-analysis. *Clin Chem Lab Med.* 2020;58(7):1021–8. <https://doi.org/10.1515/cclm-2020-0369>.
- [4] Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol.* 2005;5 13, indexed in Pubmed: 15840177.

Lukasz Szarpak

*aMaria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland*

*bMaria Sklodowska-Curie Medical Academy in Warsaw, Warsaw, Poland*  
*cPolish Society of Disaster Medicine, Warsaw, Poland*

\*Corresponding author at: Maria Sklodowska-Curie Medical Academy in Warsaw, 12 Solidarnosci Av., 03–411 Warsaw, Poland.

E-mail address: [lukasz.szarpak@gmail.com](mailto:lukasz.szarpak@gmail.com)

Kurt Ruetzler

*dDepartments of General Anesthesiology and Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio, USA*

Kamil Safiejko

*aMaria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland*

Michal Hampel

*eDepartment of Gastroenterological and Transplant Surgery, Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Warsaw, Poland*

Michal Pruc

*cPolish Society of Disaster Medicine, Warsaw, Poland*

Luiza Kanczuga - Koda

*aMaria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland*

Krzysztof Jerzy Filipiak

*f1st Chair and Department of Cardiology, Medical University of Warsaw, Poland, Warsaw*

Milosz Jaroslaw Jaguszewski

*g1st Department of Cardiology, Medical University of Gdansk, Gdansk, Poland*

12 November 2020